The FDA has agreed to review GSK’s request to approve Blenrep as a second-line combination treatment for multiple myeloma.| Rare Cancer News
Phase 3 trial in nearly 500 advanced disease patients found combination therapy using Blenrep more effective at extending life than Darzalex.| Rare Cancer News